ADULT GLIOMA: U87




FIG. 1

ADULT GLIOMA: U373




FIG. 2

PEDIATRIC GLIOMA: HSJD-DIPG-007




FIG. 3

PEDIATRIC GLIOMA: HSJD-DIPG-011




FIG. 4

PEDIATRIC GLIOMA: HSJD-GBM-001




FIG. 5

RETINOBLASTOMA: HSJD-RBT-5




FIG. 6

RETINOBLASTOMA: HSJD-RBT-7




FIG. 7

RETINOBLASTOMA: HSJD-RBT-14




FIG. 8



EWING SARCOMA: A673
% of control
100
50
0
10-6 10-5 10-4 10-3 10-2 10-1 100 101 102
Concentration (μM)
G2B-001
SN-38
Irinotecan

FIG. 9



RHABDOMYOSARCOMA: Rd
% of control
100
50
0
10-6 10-5 10-4 10-3 10-2 10-1 100 101 102
Concentration (μM)
G2B-001
SN-38
Irinotecan

FIG. 10



RHABDOMYOSARCOMA: RH4
% of control
100
50
0
10-6 10-5 10-4 10-3 10-2 10-1 100 101 102
Concentration (µM)
SN-38
G2B-001
Irinotecan

FIG.11



NEUROBLASTOMA: LAN-1
% of control
100
50
0
10-6 10-5 10-4 10-3 10-2 10-1 100 101 102
Concentration (µM)
G2B-001
SN-38
Irinotecan

FIG. 12



NEUROBLASTOMA: SK-N-JD
% of control
100
50
0
10-6 10-5 10-4 10-3 10-2 10-1 100 101 102
Concentration (μM)
G2B-001
SN-38
Irinotecan

FIG. 13



NEUROBLASTOMA: HSJD-NB-004
% of control
100
50
0
10-6 10-5 10-4 10-3 10-2 10-1 100 101 102
Concentration (μM)
G2B-001
SN-38
Irinotecan

FIG. 14

NEUROBLASTOMA: HSJD-NB-005

NEUROBLASTOMA: HSJD-NB-005




FIG. 15

NEUROBLASTOMA: HSJD-NB-016




FIG. 16



P < 0.0001
P < 0.0001
P = 0.9958
100
10
1
0.1
0.01
0.001
0.0001
0.00001
IC50 (µM)
G2B-001
SN-38
Irinotecan

FIG. 17



Mouse weight (g)
20
10
0
0
5
10
15
Days
Control
Treated

FIG. 18



Weight variation
(% of maximum weight)
0
-10
-20
-30
0 5 10 15 20 25 30 35 40
Days of treatment
Control
Irinotecan
G2B-001

FIG.19



PEDIATRIC GLIOMA: HSJD-DIPG-007
% of control
100
50
0
10-6 10-5 10-4 10-3 10-2 10-1 100
Concentration (μM)
G2B-001
SN-38
Comparative example 2

FIG. 20



PEDIATRIC GLIOMA: HSJD-GBM-001
% of control
100
50
0
10-6 10-5 10-4 10-3 10-2 10-1 100
Concentration (μM)
G2B-001
SN-38
Comparative example 2

FIG. 21



PEDIATRIC GLIOMA: HSJD-DIPG-007
% of control
100
50
0
10-3 10-2 10-1 100
Concentration (μM)
G2B-001
Comp. Ex. 1
Comp. Ex. 2

FIG. 22



PEDIATRIC GLIOMA: HSJD-GBM-001
% of control
120
100
80
60
40
20
10-3
10-2
10-1
100
Concentration (µM)
G2B-001
Comp. Ex. 1
Comp. Ex. 2

FIG. 23



% Compound G2B001
120
100
80
60
40
20
0
0
200
400
600
800
1000
1200
1400
1600
Time (min)

FIG. 24



100
50
0
% remaining
0 1 4 8 24 0 1 4 8 24 0 1 4 8 24 0 1 4 8 24
Time (h)
G2B-001_H
G2B-001_M
G2B-001_D
G2B-001_R

FIG. 25



100
50
0
% recovery vs. t=0
0.0 0.5 1.0 2.0 4.0 8.0 24.0
Time (h)
G2B-001L_H

FIG 26



PEDIATRIC GLIOMA: HSJD-DIPG-007
% of control
100
50
0
10-6 10-5 10-4 10-3 10-2 10-1 100 101 102
Concentration (μM)
G2B-001
SN-38
G2B-001 lineal

FIG. 27



NEUROBLASTOMA: HSJD-NB-013
Tumor volume (mm3)
2000
1500
1000
500
0
0
15
30
45
Days
Saline
Irinotecan
G2B-003

FIG. 28